Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.

Trial Profile

Saxagliptin and Atherosclerosis. A Possible Role for Saxagliptin in the Prevention of Atherosclerosis Beyond Glucose Metabolism.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2014

At a glance

  • Drugs Saxagliptin (Primary)
  • Indications Atherosclerosis; Type 2 diabetes mellitus
  • Focus Biomarker; Pharmacodynamics
  • Acronyms SAXATH
  • Most Recent Events

    • 16 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 21 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top